Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants

TORONTO and CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
February 11, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference

TORONTO and CAMBRIDGE, Mass, Feb. 11, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
February 06, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference

TORONTO and CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
January 29, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020

TORONTO and CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
January 15, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 15, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
January 09, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum

TORONTO and CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
January 08, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020

TORONTO and CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
December 31, 2019 13:54 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Completes Second Closing of Private Placement

NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 31, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (TSX: PMN)...
December 10, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news

TORONTO and CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
December 05, 2019 12:50 ET | Source: ProMIS Neurosciences Inc.

Aducanumab is good; next generation Alzheimer’s disease therapies will be better

TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...